Roy A. Whitfield
CIK: 0000936728
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NKTR
NEKTAR THERAPEUTICS
Director
Discretionary Trading P&L
Holdings
About WHITFIELD ROY A
WHITFIELD ROY A (SEC CIK 0000936728) files insider reports with the SEC as Director of NEKTAR THERAPEUTICS (NKTR).
Signal8 holds 3 ownership filings by WHITFIELD ROY A (2 Form 4, 1 Form 5), filed between Jan 17, 2025 and Sep 25, 2026. Those filings report 3 transactions, from Sep 18, 2024 to Sep 23, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on WHITFIELD ROY A's filings is in SAN FRANCISCO, CA.
Recent filings by WHITFIELD ROY A
Other insiders filing for NEKTAR THERAPEUTICS (NKTR)
- GREER R SCOTT, Director
- CHESS ROBERT, Director
- Brainard Diana, Director
- Ajer Jeffrey Robert, Director
- Zalevsky Jonathan, Chief R&D Officer
- ROBIN HOWARD W, President & CEO